Equazine-M en es it fr

Equazine-M Brand names, Equazine-M Analogs

Equazine-M Brand Names Mixture

  • No information avaliable

Equazine-M Chemical_Formula


Equazine-M RX_link

No information avaliable

Equazine-M fda sheet

Equazine-M msds (material safety sheet)

Equazine-M Synthesis Reference

No information avaliable

Equazine-M Molecular Weight

309.469 g/mol

Equazine-M Melting Point

< 25 oC

Equazine-M H2O Solubility

Soluble as HCl salt

Equazine-M State


Equazine-M LogP


Equazine-M Dosage Forms

Tablets (oral, 1 mg)

Equazine-M Indication

Used for the symptomatic treatment of parkinsonism.

Equazine-M Pharmacology

Metixene is a tertiary antimuscarinic with actions similar to those of atropine; it also has antihistaminic and direct antispasmodic properties. It is used for the symptomatic treatment of parkinsonism, including the alleviation of the extrapyramidal syndrome induced by other drugs such as phenothiazines, but, like other antimuscarinics, it is of no value against tardive dyskinesias. Metixene has been discontinued.

Equazine-M Absorption

Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.

Equazine-M side effects and Toxicity

Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.

Equazine-M Patient Information

Equazine-M Organisms Affected

Humans and other mammals